Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chewing gum tested as surprising remedy for medication side effect

NCT ID NCT07158359

Symptom relief Sponsor: Centre Hospitalier de Cadillac Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study tests whether chewing gum can reduce excessive drooling caused by psychiatric medications. Researchers will compare 46 adults who chew gum as part of a swallowing program to those who don't. The goal is to find a simple, non-drug solution for this uncomfortable side effect.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chewing gum
What this could lead to
If it works, this could offer a simple, drug-free way to manage drooling caused by psychiatric medications.
What could go wrong
This is a small pilot study with only 46 people, so results may not apply widely. Chewing gum might not reduce saliva enough to make a real difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 65 years. * Hospitalized at Cadillac Hospital, either in full inpatient care or at the rehabilitation facility, excluding the UHSA. * Experiencing iatrogenic hypersalivation induced by psychotropic medications. * Salivary flow causing functional impairment for the patient, or observed by family members or healthcare providers. * With or without pharmacological management of hypersalivation. * Individuals under legal protective measures may be included. * Provided written informed consent prior to participation. Exclusion Criteria: * Anatomical/morphological anomaly affecting mastication/swallowing * Swallowing disorder of organic etiology (e.g., neurological deficit due to stroke, neurodegenerative disease, oropharyngeal surgery, etc.) * Known risk of aspiration with liquids * Patient refusal of chewing gum or inability to obtain consent (e.g., non-communicative patients) * Oral/dental condition preventing mastication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypersialorrhea (excessive salivation) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psychiatric disorder Sialorrhea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypersialorrhea (excessive salivation) Psychiatric disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.